EL7.AI
StocksMedium•16 November 2026•
4 min read

Medline Shareholders Offer 60 Million Shares for Sale, Company Gets No Proceeds

Key Facts

1Shareholders are offering 60,000,000 Class A shares, and Medline will receive no sale proceeds.
2Underwriters can buy up to 9,000,000 additional shares within 30 days of the prospectus date.
3The private repurchase of shares and partnership units totals $200 million.
4The company raised its 2026 organic sales growth outlook to 10.0%-10.5%.

Medline shareholders filed a preliminary prospectus to sell 60,000,000 Class A shares in an offering from which the company will receive no proceeds, according to a filing with the U.S. Securities and Exchange Commission on November 16, 2026. The prospectus allows underwriters to purchase up to 9,000,000 additional shares from the selling shareholders within 30 days of its date. The option would allow underwriters to increase the number of shares offered if exercised, while the proceeds would remain with the selling shareholders. In parallel, Medline and Medline Holdings agreed to buy Class A shares and partnership units directly from those sellers for a total of $200 million. The repurchase will be carried out in a private, non-underwritten transaction at a per-unit price equal to the price paid by underwriters in the offering.

The repurchase is conditional on completion of the offering, with the company expecting the two transactions to close simultaneously, but the offering itself is not conditional on completion of the repurchase. According to the filing, at an assumed purchase price of $39.47 per unit, $200 million would equal about 5,067,128 shares and units. That price is Medline's closing share price on November 13, 2026, according to the prospectus. At that assumption, the repurchase represents part of the shares and units that shareholders are selling directly to the company and its affiliate. This does not change the fact that Medline will not receive proceeds from the sale of the offered shares.

The transaction follows the board's authorization in October of a program to repurchase up to $1 billion of Class A shares and/or Medline Holdings units. The company also said it prepaid $750 million of principal on its refinanced loan due in 2033. These steps place the current repurchase within a broader program announced by the company, while the current transaction remains limited to $200 million and conditional on completion of the offering. The assumed repurchase price is based on the stock's November 13 close, before the preliminary prospectus was filed the following day. The available information does not include a final offering price.

In third-quarter 2026 results, Medline's net sales rose 10.4% to $7.9 billion, compared with $7.1 billion in the same period of 2025, while organic sales increased 10.5%. Net income, however, fell 1.2% to $318 million from $322 million a year earlier. The company attributed the decline in income mainly to higher inventory costs related to inflation, increased operating expenses and customer mix. Adjusted EBITDA, meanwhile, rose 11.8% to $960 million from $859 million. The company linked the increase to higher sales and net benefits from tariff refunds.

Medline said it recorded a net benefit from refunds of fees under the International Emergency Economic Powers Act of $81 million in the third quarter and $324 million in the first nine months of 2026. The amounts included fee refunds of $70 million and $402 million, respectively. Net sales in the first nine months totaled $22.9 billion, up 10.9% from $20.6 billion in the same period of 2025. Net income for the period, however, declined 28.8% to $696 million. Chief Executive Jim Boyle said the company continues to expand capacity and introduce new technologies across its distribution network as part of its strategic priorities.

Medline raised its 2026 organic sales growth outlook to a range of 10.0%-10.5%, from its previous range of 9.0%-10.0%. It kept its adjusted EBITDA outlook at $3.3-$3.4 billion. The company said the outlook excludes benefits from refunds of fees under the International Emergency Economic Powers Act. The guidance update follows organic sales growth of 10.5% in the third quarter, while the company said sales momentum reflects continued expansion of its business. The repurchase tied to the offering remains conditional on its completion, under the terms of the preliminary filing.

Open on chart